Proactive Investors - Run By Investors For Investors

VolitionRx closes offering, raises US$8.4mln

The cancer blood test firm issued 3.5mln shares at US$2.40 a share in the offering
VolitionRx closes offering, raises US$8.4mln
The group is focused on developing simple blood tests designed to help diagnose a range of cancers

Cancer testing firm VolitionRx Ltd (NYSE:VNRX) has raised US$8.4mln gross via its previously announced public offering, now closed.

It issued 3.5mln shares at US$2.40  a share.

"Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes," it said in the brief stock market statement Tuesday.

Oppenheimer & Co Inc. acted as the sole book-running manager.

Shares closed on Tuesday at US$2.34 each.

View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 16 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use